Abstracts tagged "insulin resistance and psoriasis"

Abstract Number: 2203 • 2014 ACR/ARHP Annual Meeting
Adalimumab Therapy Improves Insulin Sensitivity in Non-Diabetic Psoriatic Patients: A 6-Month Prospective Study
Trinitario Pina Murcia¹, Raquel López-Mejías¹, Fernanda Genre¹, Begoña Ubilla¹, Susana Armesto², Marcos A. González-López², María del Carmen Gonzalez-Vela³, Javier Llorca⁴, Ricardo Blanco⁵ and MA González-Gay¹, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Dermatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Dept. of Pathology, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁵Hospital Marques de Valdecilla, Santander, Spain
Background/Purpose: psoriasis is a systemic inflammatory condition that shares similarities with other inflammatory immune disorders. In this context, patients with psoriasis are at an increased…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].